
A pediatric dermatologist explains how to read itch, sleep, and quality-of-life findings from phase 2 nemolizumab data in children aged 2 - 11.
In this episode, the topics up for discussion include possible technologies to help atopic dermatitis patient adherence with treatment along with new strategies to improve patient experiences at the practice.


